The company operates across three distinct segments: trading petroleum products, manufacturing bitumen emulsion for road construction, and providing biomedical waste management services including the manufacture of disinfection systems.
The company lacks a durable competitive advantage, as evidenced by negative average ROCE (-21.5%) and ROE (-23.6%). While it operates in regulated sectors like biomedical waste, its small scale and weak financial returns indicate it is a price-taker in commodity-like markets.
Capital allocation has been poor, with reinvested earnings failing to generate positive returns on capital. The company maintains a high dividend payout despite negative returns on equity, suggesting a lack of internal high-return reinvestment opportunities.
The business collapsed as the circular flow of capital between the company and related parties finally hit a liquidity wall. By 2029, the persistent inability to generate positive returns on capital (ROCE) meant that every rupee of growth actually destroyed value, while the high dividend payouts further hollowed out the balance sheet. The lack of a competitive advantage in commodity-like waste and energy markets led to terminal stagnation, and the market eventually re-rated the stock to reflect its true status as a value-destroying vehicle for promoter interests rather than a productive enterprise.
RichFakir rates Sanmit Infra Ltd's business quality as poor — 22/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sanmit Infra Ltd is trading about 61% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sanmit Infra Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sanmit Infra Ltd's fair value is about ₹28 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →